SCHEMBL1500481

SCHEMBL1500481

CC(C)(O)Cc1ccc2cc(Br)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.46
HDAC1 Q13547 4/20 0.45
HDAC2 Q92769 4/20 0.45
TLR2 O60603 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX5AP P20292 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
PPARA Q07869 1/20 0.33
DPP4 P27487 1/20 0.33
CYP2A6 P11509 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14925243 0.78 BACE1 (0.53) BACE1HDAC1HDAC2TLR2CYP2C19
SCHEMBL30718905 0.78 BACE1 (0.53) BACE1HDAC1HDAC2TLR2CYP2C19
SCHEMBL5050008 0.78 BACE1 (0.53) BACE1HDAC1HDAC2TLR2CYP2C9
SCHEMBL13924681 0.76 CYP1A2 (0.50) ALDH1A1MAPTLMNAGAA
SCHEMBL2322461 0.75 BACE1 (0.55) BACE1HDAC1HDAC2TLR2CYP2C19
SCHEMBL13825563 0.75 BACE1 (0.44) BACE1HDAC1HDAC2TLR2CYP3A4
SCHEMBL14930076 0.75 HDAC1 (0.41) BACE1HDAC1HDAC2TLR2CYP3A4
SCHEMBL1641368 0.75 BACE1 (0.50) BACE1HDAC1HDAC2TLR2CYP2C19
SCHEMBL22110670 0.75 BACE1 (0.50) BACE1HDAC1HDAC2TLR2CYP3A4
SCHEMBL2556988 0.75 BACE1 (0.50) BACE1HDAC1HDAC2TLR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-30 US disclosed
US-7902369-B2 Diaryl-substituted five-membered heterocycle derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE OPRK1, GRM1, GRIK1 BACE1 1741/4885HDAC1 1337/4885HDAC2 1712/4885
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 BACE1 1861/4885HDAC1 1543/4885HDAC2 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.